Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer

Inclusion Criteria

• •Histologically or cytologically confirmed endometrial (endometrioid, uterine, papillary serous carcinoma, and carcinosarcoma), ovarian (primary peritoneal/fallopian tube, serous, endometrioid, mixed, and poorly differentiated epithelial ovarian cancers \[for purposes of eligibility, carcinosarcoma is considered a poorly differentiated carcinoma\]), hepatocellular carcinoma, carcinoid or islet cell (neuroendocrine: well- or moderately-differentiated neuroendocrine) cancer which are locally advanced, recurrent, or metastatic
• •Patients must have measurable disease; patients having only lesions measuring \>= 1 cm to \< 2 cm must use spiral computed tomography (CT) imaging for both pre- and post-treatment tumor assessments; patients who have had prior palliative radiotherapy to metastatic lesion(s) must have at least one measurable lesion(s) that have not been previously irradiated
• •Radiation therapy (adjuvant or palliative) must be completed \>= 4 weeks prior to registration, if applicable
• •Absolute neutrophil count (ANC) \>= 1500/mm\^3
• •Platelets \>= 75,000/mm\^3
• •Hemoglobin \>= 9.0 g/dL
• •Total bilirubin =\< 1.5 x upper limit of normal (ULN); Note: direct bilirubin and international normalized ratio (INR) for hepatocellular carcinoma (HCC) patients allowed as per Child-Turcotte-Pugh scoring
• •Alkaline phosphatase =\< 2.5 x ULN (=\< 5 x ULN if liver metastasis is present or patient is in HCC cohort)
• •Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase \[AST\]) =\< 2.5 x ULN (=\< 5 x ULN if liver metastasis is present or patient is in HCC cohort)
• •Creatinine =\<1.5 x ULN
• •Urinalysis \< 2+ protein; urine protein should be screened by dipstick or urine analysis; for proteinuria \>= 2+, 24-hour urine protein should be obtained and the level should be \< 2 g for patient enrollment
• •Fasting serum cholesterol =\< 350 mg/dL (=\< 9.0 mmol/L)
• •Triglycerides =\< 1.5 x ULN (mg/dL or mmol/L); patients with triglyceride levels \> 1.5 x ULN can be started on lipid lowering agents and reevaluated within 1 week; if levels go to =\< 1.5 x ULN, they can be considered for the trial and continue the lipid lowering agents; NOTE: cholesterol and triglyceride measurement and management are not required for single-agent bevacizumab cohort with islet cell carcinoma
• •International normalized ratio (INR) =\< 1.5 (unless the patient is on full dose warfarin)
• •Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1
• •Capable of understanding the investigational nature, potential risks and benefits of the study and able to provide valid informed consent
• •Negative serum pregnancy test done =\< 7 days prior to registration, for women of childbearing potential only; NOTE: patients and their partners should be practicing an effective form of contraception during the study and for at least 3 months following the last dose of this combined therapy
• •Full-dose anticoagulants, if a patient is receiving full-dose anticoagulants (except carcinoid tumors), the following criteria should be met for enrollment: the subject must have an in-range INR (usually between 2 and 3) on a stable dose of warfarin or on stable dose of low molecular weight (LMW) heparin
• •Prior systemic treatments for metastatic disease are permitted, including targeted therapies, biologic response modifiers, chemotherapy, hormonal therapy, or investigational therapy; exception: in the case of endometrial cancer no prior chemotherapy for metastatic or recurrent disease is allowed; prior planned adjuvant chemotherapy is allowed
• •Patients who have had prior anthracycline must have a normal ejection fraction on left ventricular ejection fraction (LVEF) assessment by multigated acquisition scan (MUGA) or echocardiogram (Echo) =\< 4 weeks prior to registration
• •Availability of tissue if applicable (from the primary tumor or metastases) for tumor studies for banking; Note: in the case of hepatocellular cancer if diagnosed by clinical and radiologic criteria only, availability of tissue not applicable
• •Willingness to donate blood for biomarker studies related to the type of therapies used in this trial and the tumor types being treated
• •ENDOMETRIAL CANCER (PERMANENTLY CLOSED TO ENROLLMENT)
• •Any hormonal therapy directed at the malignant tumor is allowed; NOTE: therapy must be discontinued at least one week prior to registration
• •Prior systemic therapy including biologic and immunologic agents as adjuvant treatment, must be discontinued at least 3 weeks prior to registration
• •Recurrent or persistent endometrial adenocarcinoma, uterine papillary serous carcinoma and carcinosarcoma which is refractory to curative therapy or established treatments; NOTE: histologic or cytologic confirmation of original primary tumor is required
• •HEPATOCELLULAR CANCER (PERMANENTLY CLOSED TO ENROLLMENT)
• •HCC confirmed by biopsy OR diagnosed by clinical and radiologic criteria; all of the following criteria must be met or a biopsy is required:
• •* Known cirrhosis or chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection
• •* Hypervascular liver masses \> 2 cm, and either serum alpha-fetoprotein (AFP) \> 400 ng/ml, or
• •* AFP \> three times normal and doubling in value in the antecedent 3 months
• •Child-Pugh A (=\< 6 points) or better liver status
• •Prior regional treatments for liver metastasis are permitted including:
• •* Selective internal radiation therapy such as brachytherapy, cyberknife, radiolabeled microsphere embolization, etc.
• •* Hepatic artery chemoembolization
• •* Hepatic artery embolization
• •* Hepatic artery infusional chemotherapy
• •* Radiofrequency ablation NOTE: patients must be \>= 4 weeks from treatment and show progressive disease in the liver after regional therapy or must have measurable disease outside the liver
• •Concomitant anti-viral therapy is allowed
• •History of prior varices or evidence of varices on pre-study CT/magnetic resonance imaging (MRI) imaging are required to undergo endoscopy =\< 4 weeks prior to registration; those who had received specific therapy (banding and/or sclerotherapy) and had not bled within the prior 6 months are eligible
• •Suitably recovered from prior localized therapy, in the opinion of the investigator
• •ISLET CELL CANCER AND CARCINOID TUMOR (PERMANENTLY CLOSED TO ENROLLMENT)
• •Patient has evidence of progressive disease as documented by Response Evaluation Criteria in Solid Tumors (RECIST) =\< 7 months prior to study entry
• •Carcinoid tumor cohort: prior and concurrent long-acting somatostatin analogue therapy is required; patient has to be on a stable dose of a long-acting somatostatin analogue \>= 2 months prior to study entry with documentation of progressive disease on current dose
• •Islet cell tumor cohort: prior and/or concurrent long-acting somatostatin analogue therapy is allowed, but not required; if patient is continued on a long-acting somatostatin analogue, a stable dose for \>= 2 months prior to study entry is required with documentation of progressive disease on current dose
• •Prior therapies allowed include:
• •* =\< 2 prior chemotherapy regimens
• •* Prior interferon \>= 4 weeks prior to registration
• •* Radiolabeled octreotide therapy (patients with prior radiolabeled octreotide therapy should have progressive disease after such therapy)
• •* Other investigational therapy NOTE: islet Cell Single Agent Bevacizumab Cohort: Prior mammalian target of rapamycin (mTOR) inhibitor is allowed
• •Prior regional treatments for liver metastasis are permitted including:
• •* Selective internal radiation therapy such as brachytherapy, cyberknife, radiolabeled microsphere embolization, etc.
• •* Hepatic artery chemoembolization
• •* Hepatic artery embolization
• •* Hepatic artery infusional chemotherapy
• •* Radiofrequency ablation NOTE: patients must be \>= 12 weeks from treatment and show progressive disease in the liver after regional therapy or must have measurable disease outside the liver